Prise en charge de la maladie hépatique stéatosique associée à un dysfonctionnement métabolique (MASLD)
These new EASL-EASD-EASO guidelines on the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) recommend VCTE™ to measure liver stiffness with the specific cut-off value of 8 kPa in the stepwise strategy for non-invasive assessment of the risk for advanced fibrosis.
This new joint EASL-EASD-EASO Clinical Practice Guidelines provides an update on definitions, prevention, screening, diagnosis and treatment for MASLD.
It’s essential to identify liver steatosis, a key feature of MASLD, that should lead to assessing advanced liver fibrosis — a predictor of liver-related outcomes.
EASL-EASD-EASO Clinical Practice Guidelines – Update 2024